Verified
YURPEAK 7.5MG KWIKPEN
Manufacturer CIPLA LIMITED

YURPEAK 7.5MG KWIKPEN

Yurpeak 7.5 mg KwikPen is a pre-filled injectable containing Tirzepatide, a dual GIP and GLP-1 receptor agonist designed for adults with Type 2 diabetes. It supports improved blood sugar control and meaningful weight loss when used alongside diet and exercise. Administered subcutaneously once weekly, this maintenance dose follows initial lower strengths for better tolerability.

₹ 20,625.00

Inclusive of all taxes • Best Price Guaranteed

Product Details

Brand CIPLA LIMITED
Salt Composition TIRZEPATIDE 7.5MG
Package Size 1*3ML

Description

Blog

Yurpeak 7.5 mg (Tirzepatide): Complete Guide for Diabetes & Weight Management in India 2026

The arrival of Yurpeak (Tirzepatide) in India has opened a powerful, more affordable option for patients with Type 2 diabetes – especially those who also need substantial weight loss. As a once-weekly injection, Yurpeak 7.5 mg offers the same dual hormone action as original Tirzepatide brands, but at a more accessible price point. Endocrinologists across India are increasingly recommending Tirzepatide-based therapies for suitable patients. Many report that people on a 7.5 mg weekly dose are not only achieving excellent blood sugar control, but also losing a meaningful percentage of body weight – often in the 12–18% range over time. However, with MRP around ₹20,625 per pen, cost and availability can still be challenges. This comprehensive guide covers everything you need to know about Yurpeak 7.5 mg KwikPen – how it works, who it’s for, dosing, side effects, and how to get it at PowerNosh wholesale price ₹16,500 through our verified supply network.

Product Overview – Yurpeak 7.5mg KwikPen

Attribute Details
Product Name Yurpeak® 7.5mg KwikPen
Active Ingredient Tirzepatide
Strength 7.5 mg
Dosage Form Pre-filled Injectable KwikPen
Injection Volume 0.5 ml
Drug Class GLP-1 / GIP Dual Receptor Agonist
Indication Type 2 Diabetes Mellitus & Weight Management (as prescribed)
Dose Frequency Once weekly
Route of Administration Subcutaneous injection
Injection Sites Abdomen, thigh, or upper arm
Starter / Maintenance Maintenance dose (after 5 mg escalation)
Mechanism of Action Improves insulin secretion, reduces glucagon release, slows gastric emptying, and suppresses appetite
Pack Type Multi-dose prefilled KwikPen
Prescription Status Prescription only (Rx)
Storage Conditions Refrigerate at 2–8°C (Do not freeze)
Manufacturer Cipla Ltd
Country of Origin India
Suitable For Adults with Type 2 Diabetes under medical supervision
Common Side Effects Nausea, vomiting, diarrhea, decreased appetite (usually mild & temporary)
Special Precautions Not recommended in patients with history of MEN-2 or medullary thyroid carcinoma
Availability Available at PowerNosh
Cold Chain Maintained

🏥 Looking for Authentic Yurpeak 7.5 mg at Best Price? PowerNosh offers genuine Yurpeak 7.5 mg at wholesale price ₹16,500/pen (MRP ₹20,625)

CHECK AVAILABILITY → ✅ 100% Authentic | ✅ Cold Chain Maintained | ✅ Direct from Authorized Distributors


What is Yurpeak 7.5 mg?

Yurpeak 7.5 mg is a brand of Tirzepatide, a once-weekly injectable medicine used for the treatment of Type 2 diabetes in adults. It belongs to a new class of drugs that act as a dual GIP and GLP‑1 receptor agonist, and is given as a pre-filled pen (similar in design and function to other Tirzepatide KwikPens). The 7.5 mg strength is typically used after patients have tolerated lower starting doses (usually 2.5 mg for 4 weeks, then 5 mg for 4 weeks). From there, dose may be escalated further (10 mg, 12.5 mg, 15 mg) depending on blood sugar response and tolerability, as guided by the treating physician.

Key Facts About Yurpeak 7.5 mg:

Aspect Details
Active Ingredient Tirzepatide
Brand Name Yurpeak 7.5 mg KwikPen (Tirzepatide)
Drug Class Dual GIP and GLP‑1 receptor agonist
Form Pre‑filled KwikPen – 0.5 mL solution for injection
Strength 7.5 mg/0.5 mL
Route Subcutaneous injection (under the skin), once weekly
Usual Use Type 2 diabetes with or without obesity
Storage Refrigerated at 2–8°C; protect from light; do not freeze
Prescription Required Yes (Prescription-only / Schedule H equivalent)

How Does Yurpeak (Tirzepatide) 7.5 mg Work? The Dual‑Action Mechanism

Tirzepatide (the active ingredient in Yurpeak) is unique because it activates two incretin hormone receptors in the body:
  1. GIP – Glucose‑dependent Insulinotropic Polypeptide Receptors
  2. GLP‑1 – Glucagon‑like Peptide‑1 Receptors
Most older diabetes injections only work via the GLP‑1 pathway. By acting on both GIP and GLP‑1 receptors, Yurpeak 7.5 mg can deliver more powerful effects on blood sugar and weight. This dual action leads to:
  • Enhanced insulin secretion from the pancreas when blood sugar is high
  • Reduced glucagon release, which lowers excess glucose production by the liver
  • Slower gastric emptying, helping you feel full for longer after meals
  • Reduced appetite and cravings, aiding in calorie reduction
  • Improved insulin sensitivity in muscles and fat tissue

📊 Clinical Data (Tirzepatide Trials): In large clinical trials, weekly Tirzepatide at 7.5 mg and above has shown:

• HbA1c reductions of around 2.0–2.3% • Average weight loss of 9–11 kg over 40 weeks (higher at higher doses)

Primary Uses and Benefits of Yurpeak 7.5 mg

1. Type 2 Diabetes Management

Approved Indication (molecule level): Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. Expected Benefits with 7.5 mg Dose:
  • Significant HbA1c reduction (≈2.0–2.3%) over time
  • Improved fasting blood glucose (often 45–55 mg/dL reduction)
  • Better post‑meal sugar control throughout the day
  • Increased “time in range” for CGM users (by 18–25%)

2. Weight Management (Off‑label in India, but Clinically Observed)

While formal, labeled weight loss indications may vary by country, real‑world experience and international data show that tirzepatide can support substantial weight reduction, especially at 7.5 mg and higher doses:
  • Average weight loss of 12–18% of baseline body weight with continued therapy
  • Decreases in waist circumference (9–12 cm)
  • Improvement in BMI category (e.g., from obese to overweight)
  • Better control of weight‑related issues like fatty liver, sleep apnea, and joint strain (when combined with lifestyle changes)

3. Potential Cardiometabolic Benefits

Early data and ongoing studies suggest that tirzepatide (Yurpeak) may offer additional benefits:
  • Blood pressure: Reduction of 6–8 mmHg systolic in many patients
  • Triglycerides and LDL cholesterol; ↑ HDL cholesterol
  • Inflammatory markers, which may lower cardiovascular risk long‑term

Yurpeak 7.5 mg Dosing Schedule

Yurpeak 7.5 mg is not the initial starting dose. Most patients are started at 2.5 mg once weekly and then gradually increased based on tolerability and response.
Week Recommended Weekly Dose* Purpose
Weeks 1–4 2.5 mg once weekly Starter dose to allow the body to adapt
Weeks 5–8 5 mg once weekly First therapeutic dose – stronger sugar and weight effect
Weeks 9–12 7.5 mg once weekly Further titration for enhanced control
Week 13+ May increase to 10 mg, etc. Further titration as needed, up to max 15 mg weekly
*Always follow the exact titration plan prescribed by your doctor. Do not change the dose on your own.

How to Use Yurpeak 7.5 mg KwikPen (Tirzepatide Pen)

Step‑by‑Step Injection Guide

  1. Preparation:
    • Take the pen out of the refrigerator about 30 minutes before injecting so it can reach room temperature (this reduces injection discomfort).
    • Check the expiry date on the carton and pen.
    • Inspect the solution through the window – it should be clear, colorless to slightly yellow, with no particles.
    • Wash your hands thoroughly with soap and water.
  2. Choose Injection Site:
    • Preferred sites:
      • Abdomen (stomach) – at least 2 inches away from the navel
      • Front of the thigh
      • Upper arm (back of the arm, if someone else is giving the injection)
    • Rotate injection sites each week to avoid skin irritation and lumps.
  3. Injection Process:
    • Clean the selected area with an alcohol swab and let it dry.
    • Remove the pen cap.
    • Place the pen’s clear base flat and firmly against the skin at a 90‑degree angle.
    • Press and hold the injection button as directed (depending on pen design) – in most devices, you will:
      • Hear the first click (injection starts)
      • Hold for a few seconds until you hear the second click (injection completes)
    • Count slowly to 5–10 after the second click before removing the pen, to ensure full dose is delivered.
  4. After Injection:
    • Remove the pen and dispose of it in a sharps container – most Tirzepatide pens are single‑use.
    • Do not reuse the pen.
    • Record the date, time, and site in your logbook or app.
    • Store new, unused pens back in the refrigerator (2–8°C).

Yurpeak 7.5 mg Side Effects and Their Management

Side effects with Yurpeak 7.5 mg are generally similar to those seen with other Tirzepatide products. Many are gastrointestinal and often improve over time as the body adapts.

Common Side Effects (often mild to moderate):

Side Effect How Common? Management Tips
Nausea Up to 15–20% of patients Eat smaller, more frequent meals; avoid very fatty or spicy foods; take injection on a day you can rest.
Diarrhea 10–15% Maintain hydration; use oral rehydration solutions; follow a bland “BRAT” diet (Banana, Rice, Apple sauce, Toast) temporarily.
Vomiting 5–8% Consult your doctor; anti‑nausea medicines may be prescribed if needed.
Constipation 5–7% Increase fiber (fruits, vegetables, oats) and water intake; gentle exercise like walking can also help.
Indigestion / Heartburn Some patients Avoid late night large meals; elevate head while sleeping; discuss antacids with your doctor.
Injection site reactions 3–5% Rotate sites each week; usually mild redness or itching resolves on its own.

Serious Side Effects (Seek Immediate Medical Attention):

  • Severe, persistent abdominal pain that may radiate to the back (could indicate pancreatitis)
  • Signs of an allergic reaction: rash, swelling of face/lips/tongue, difficulty breathing
  • Changes in vision (especially if you already have diabetic retinopathy)
  • Possible symptoms related to thyroid tumors (e.g., neck lump, hoarseness, difficulty swallowing)
  • Severe hypoglycemia (especially when used with insulin or sulfonylureas): confusion, sweating, shaking, rapid heartbeat
Always report unusual or severe symptoms to your doctor promptly.

Yurpeak 7.5 mg Price in India (2026)

The cost of advanced injectable therapies like Tirzepatide can be substantial. Knowing where to get genuine Yurpeak at the best possible price is crucial for long‑term treatment adherence.

MRP and PowerNosh Wholesale Price

Pricing Type Price per Yurpeak 7.5 mg Pen Notes
MRP (Maximum Retail Price) ₹20,625 Official printed MRP inclusive of all taxes
PowerNosh Wholesale Price ₹16,500 Flat ~20% below MRP – Save ₹4,125 per pen
At the wholesale price of ₹16,500, a typical 4‑week supply (4 pens) costs:
  • At MRP: 4 × ₹20,625 = ₹82,500
  • At PowerNosh price: 4 × ₹16,500 = ₹66,000
You save ₹16,500 per month by sourcing Yurpeak 7.5 mg via PowerNosh compared to paying full MRP.

💰 Cost‑Saving Tip: For patients on long‑term Tirzepatide therapy, saving ₹16,000+ per month can make the difference between continuing treatment vs. having to stop due to cost. PowerNosh’s wholesale pricing is designed to support sustained therapy.

How Yurpeak 7.5 mg Pricing Compares to General Market

Source Type Typical Price per Pen* Comments
Hospital / Retail Pharmacies Often near MRP (₹19,500–20,625) Occasional small discounts; limited stock in some cities
Generic Online Pharmacies ~₹18,000–19,500 (if listed) Check for seller ratings and cold chain handling
PowerNosh (Verified Wholesale) ₹16,500 Direct from authorized distributors; full cold chain; best sustainable pricing
*Exact prices vary by city, platform, and ongoing offers. Figures shown are typical ranges, not fixed rates.

Who Should Use Yurpeak 7.5 mg?

Ideal Candidates:

  • ✅ Adults with Type 2 diabetes whose blood sugar is not adequately controlled with oral medications alone
  • ✅ Patients with Type 2 diabetes and obesity (BMI ≥27) who need weight loss along with sugar control
  • ✅ Those who have tolerated 5 mg weekly without significant side effects
  • ✅ Patients at high cardiovascular risk where weight loss and better sugar control are especially important
  • ✅ Individuals who prefer a once‑weekly injection rather than daily injections or multiple tablets

Who Should NOT Use Yurpeak:

  • ❌ People with Type 1 diabetes or diabetic ketoacidosis (DKA)
  • ❌ Those with a personal or family history of medullary thyroid carcinoma
  • ❌ Individuals with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Pregnant or breastfeeding women (safety not well established)
  • ❌ Children and adolescents under 18 years
  • ❌ Patients with severe gastrointestinal disease (e.g., gastroparesis) where further slowing digestion is risky
  • ❌ Anyone with a history of severe pancreatitis should use with extreme caution and only if a specialist recommends it

Drug Interactions and Precautions

Important Drug Interactions:

Drug / Class Potential Interaction Suggested Management
Insulin Increased risk of low blood sugar (hypoglycemia) Doctor may reduce insulin dose when starting Yurpeak
Sulfonylureas (e.g., glimepiride, gliclazide) Higher hypoglycemia risk when combined Monitor sugars closely; dose adjustment may be needed
Oral contraceptive pills Possible delayed absorption due to slowed gastric emptying Take contraceptives at least 1 hour before Yurpeak; discuss with doctor
Warfarin Changes in INR in some patients More frequent INR monitoring after starting or adjusting Yurpeak dose

Storage and Handling of Yurpeak 7.5 mg

Unopened Pens:
  • Keep refrigerated at 2–8°C.
  • Do not freeze. If a pen has been frozen, it should be discarded.
  • Store in the original carton to protect from light.
In Use / Room Temperature:
  • Depending on manufacturer instructions, a pen may be kept at room temperature (usually below 25–30°C) for a limited period (e.g., up to 21–28 days). Check the specific Yurpeak pack insert.
  • Do not expose to direct sunlight or excessive heat.
Disposal:
  • Used pens should be discarded in a puncture‑resistant sharps container.
  • Do not throw used pens in regular household garbage.

Tirzepatide (Yurpeak) vs Other GLP‑1 Agonists

Feature Yurpeak (Tirzepatide) Ozempic (Semaglutide) Trulicity (Dulaglutide)
Receptor Action Dual GIP + GLP‑1 GLP‑1 only GLP‑1 only
HbA1c Reduction (approx.) Up to ~2.3% Up to ~1.8% Up to ~1.6%
Weight Loss Potential High (12–18%+) Moderate‑High (8–12%) Moderate (5–7%)
Dosing Frequency Weekly Weekly Weekly

Frequently Asked Questions (FAQs)

1. How long does it take for Yurpeak 7.5 mg to show results?

Some improvements in blood sugar can be seen within 1–2 weeks of starting tirzepatide. However, full benefits on HbA1c and weight usually become apparent over 8–12 weeks or longer, especially as doses are gradually increased under medical supervision.

2. Can I use Yurpeak 7.5 mg only for weight loss if I’m not diabetic?

Currently, in India, tirzepatide‑based products like Yurpeak are primarily used for Type 2 diabetes. Off‑label use for obesity alone should only be considered under the care of an experienced endocrinologist or obesity specialist, after weighing all risks and benefits.

3. What happens if I miss a 7.5 mg dose?

If you miss a dose and it’s been 4 days or less since your scheduled day, take it as soon as you remember. If more than 4 days have passed, skip the missed dose and take the next one at your regular weekly time. Do not double doses to make up for a missed injection.

4. Is Yurpeak 7.5 mg covered by insurance in India?

Coverage varies by insurer and policy. Many insurers recognize tirzepatide as an advanced diabetes treatment and may cover part of the cost, especially when prescribed by a specialist. Pre‑authorization and detailed documentation are often required. Always check with your insurer and keep proper invoices (PowerNosh provides GST invoices suitable for claims).

5. Can I travel with Yurpeak 7.5 mg?

Yes, but you must maintain the cold chain. Use an insulated travel pouch with ice packs, avoid direct contact of the pen with ice, and carry your prescription and a letter from your doctor if flying. Do not pack pens in checked‑in luggage where temperatures can fluctuate.

Conclusion: Yurpeak 7.5 mg – A Powerful Tool, More Affordable via PowerNosh

Yurpeak 7.5 mg (Tirzepatide) is a major step forward in both blood sugar control and weight management for people with Type 2 diabetes. It offers the dual benefits of improving glycemic control and supporting meaningful, sustained weight loss. However, such advanced therapies can be expensive at MRP. By offering wholesale pricing of ₹16,500 per pen (vs MRP ₹20,625), PowerNosh helps reduce the financial burden, making it more realistic for patients to continue treatment long‑term. Always remember: Tirzepatide should be used only under the supervision of a qualified doctor, along with proper diet, exercise, and regular monitoring.

💊 Ready to Source Yurpeak 7.5 mg at Best Price?

For Patients | For Pharmacies | For Hospitals\ 📞 Helpline: +91-8003467285| 📧 care@powernosh.com

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Always consult your healthcare provider before starting or changing any medication. Individual results vary.

Price Disclaimer: Prices mentioned (MRP ₹20,625; PowerNosh wholesale ₹16,500) are based on information available as of January 2026 and may change with time or manufacturer updates.

 

Choose Your City

At Powernosh, we are building a smarter way to connect the pharmaceutical ecosystem with opportunities and essential services. Our platform is designed to serve as a one-stop solution for professionals, businesses, and individuals.

Barcode
Head Office
Global Offices
  • 11 Studebaker Trail, Brampton, ON L7A 3A2, Canada
  • 4007 Brandywyne Dr, Troy, Michigan 48098, USA

Copyright © 2026 Partners All Rights Are Reserved.

Sidebar Menu